Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source.
IVL technology expands company’s innovative product portfolio.
MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) — Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial launch of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe. The first cases were completed by Stefano Galli, MD, Interventional Cardiologist at Centro Cardiologico Monzino in Milan, Italy; Professor Eric Van Belle, MD, Head of the Interventional Cardiology Department, Lille University Hospital, Lille, France;…